Pharmaceutical Giants Pour Billions into US Manufacturing to Hedge Against Potential Tariffs
Global drugmakers are pouring billions into U.S. manufacturing and stockpiling inventory to avoid potential tariffs. This shift aims to secure supply chains.
Insights:
The Trump administration is currently considering a 100% tariff on imported branded and patented medicines, a policy proposal that has prompted immediate and large-scale responses across the global pharmaceutical sector. As of January 30, 2026, while the measure remains under discussion, major drugmakers have already begun accelerating manufacturing investment in the United States 
US, stockpiling inventory, and securing multi-year tariff exemptions through platforms such as TrumpRx.gov. These strategic actions are aimed at avoiding potential penalties and could materially shift pharmaceutical supply chains and the overall scale of domestic production.
US, stockpiling inventory, and securing multi-year tariff exemptions through platforms such as TrumpRx.gov. These strategic actions are aimed at avoiding potential penalties and could materially shift pharmaceutical supply chains and the overall scale of domestic production.The magnitude of the industry response is marked by multi-billion-dollar investment commitments and the initiation of expedited projects. Companies including Pfizer Inc. , AstraZeneca PLC , and Eli Lilly and Company are leading the shift toward increased domestic capacity. Similarly, Johnson & Johnson and Merck & Co., Inc. are actively adjusting their footprints to mitigate the impact of the proposed trade barriers. Robert Davis robert davis, the head of Merck & Co., Inc. , is among the executives overseeing these transitions as the industry navigates the policy deliberations of Donald Trump donald trump.
